Cited by 1,046Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.

Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease

Liberatore, Gabriel T., Jackson-Lewis, Vernice, Vukosavic, Slobodanka, Mandir, Allen S., Vila, Miquel, McAuliffe, W. Geoffrey, Dawson, Valina L., Dawson, Ted M., Przedborski, Serge·1999·Nature Medicine

DOI 10.1038/70978

Open this paper in CoChat — free account

Abstract

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) damages dopaminergic neurons as seen in Parkinson disease. Here we show that after administration of MPTP to mice, there was a robust gliosis in the substantia nigra pars compacta associated with significant upregulation of inducible nitric oxide synthase (iNOS). These changes preceded or paralleled MPTP-induced dopaminergic neurodegeneration. We also show that mutant mice lacking the iNOS gene were significantly more resistant to MPTP than their wild-type littermates. This study demonstrates that iNOS is important in the MPTP neurotoxic process and indicates that inhibitors of iNOS may provide protective benefit in the treatment of Parkinson disease.

Integrity signals

Registry

Crossref · 10.1038/70978

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Free radicals in biology and medicine
Gutteridge, J. M. C. (1991) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(91)90478-o · Cited by 17,178
NITRIC OXIDE AND MACROPHAGE FUNCTION
MacMicking, J. D., Xie, Q. W., & Nathan, C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.323 · Cited by 4,245
Reactive astrocytes: cellular and molecular cues to biological function
Ridet, J., Privat, A., Malhotra, S. K., & Gage, F. H. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01139-9 · Cited by 1,766
Regulation of biosynthesis of nitric oxide.
Nathan, C., & Xie, Q. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36703-0 · Cited by 1,669
Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase
MacMicking, J. D., Nathan, C., Hom, G. J., Chartrain, N. A., Fletcher, D. S., Trumbauer, M. E., Stevens, K. A., Xie, Q. W., Sokol, K. A., Hutchinson, N. I., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90085-3 · Cited by 1,445
Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase
Bredt, D. S., Glatt, C. E., Hwang, P. M., Fotuhi, M., Dawson, T. M., & Snyder, S. H. (1991) · Neuron · doi:10.1016/0896-6273(91)90374-9 · Cited by 1,359
Self-citation
Targeted disruption of the neuronal nitric oxide synthase gene
Huang, P. L., Dawson, T. M., Bredt, D. S., Snyder, S. H., & Fishman, M. C. (1993) · Cell · doi:10.1016/0092-8674(93)90615-w · Cited by 1,303
Self-citation
Gases as biological messengers: nitric oxide and carbon monoxide in the brain
Dawson, T., & Snyder, S. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-09-05147.1994 · Cited by 1,043
Self-citation
MICROGLIA AS MEDIATORS OF INFLAMMATORY AND DEGENERATIVE DISEASES
González-Scarano, F., & Baltuch, G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.219 · Cited by 984
New stereological methods for counting neurons
West, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90112-o · Cited by 940

Show all 53 references

Research works printed but not linked: 2

Fahn, S. in Cecil's Textbook of Medicine vol.18 (eds. Wyngaarden, J.B. & Smith, L.H.Jr.) 2143–2147 (Saunders, Philadelphia, 1988).
Przedborski, S. & Jackson-Lewis, V. Mechanisms of MPTP toxicity. Mov. Disord. 13, 35– 38 (1998).

Sorted by citations

Roles of CHOP/GADD153 in endoplasmic reticulum stress
Oyadomari, S., & Mori, M. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401373 · Cited by 2,879
“stress, and overexpression of parkin confers resistance to both ER stress and mutant a-synuclein-induced toxicity.(104,105)”
Background
Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases
Tang, Y., & Le, W. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9070-5 · Cited by 2,190
“Similarly, typical characteristics of M1 phenotype including the activation of NADPH oxidase and NF-κB pathways, as well as the release of various pro-inflammatory mediators were observed in the MPTP-intoxicated models [79–81].”
Background
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Oxidative stress in neurodegeneration: Cause or consequence?
Andersen, J. K. (2004) · Nature Medicine · doi:10.1038/nrn1434 · Cited by 1,869
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
“Experimentally in the MPTP model, the gliosis in the SN is associated with significant up-regulation of iNOS [37], while inhibition of nNOS protects against MPTP toxicity [38, 39].”
Background
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
Virág, L., & Szabó, C. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.375 · Cited by 1,373
“…both the production of reactive oxygen intermediates (Przedborski et al.,; Cassarino et al., 1997; Hung and Lee, 1998) and NO-derived radicals/oxidants (Schulz et al., 1995a,b,c; Ara et al., 1998; Beal, 1998; Ferrante et al., 1999; Liberatore et al., 1999) in the pathogenesis of MPTP neurotoxicity.”
Background
Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
“…decreases MPTP-mediated nitrotyrosine formation A significant part of the MPTP neurotoxic process is mediated by NO-related oxidative damage (Przedborski et al., 2000), the extent of which can be evaluated by assessing nitrotyrosine levels (Liberatore et al., 1999; Pennathur et al., 1999).”
BackgroundMethodResultInfluential
Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease
Brochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172
Protocol for the MPTP mouse model of Parkinson's disease
Jackson-Lewis, V. R., & Przedborski, S. (2007) · Nature Protocols · doi:10.1038/nprot.2006.342 · Cited by 1,151
Self-citation
Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention
Liu, B., & Hong, J.-S. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035048 · Cited by 1,095
“For example, mice lacking inducible nitric oxide synthase activity are resistant to MPTP-induced lesions and inhibition of microglial activation reduces MPTP neurotoxicity (Itzhak et al., 1999; Liberatore et al., 1999; Dehmer et al., 2000; Du et al., 2001; Wu et al., 2002).”
Background
Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway
Lehnardt, S., Massillon, L., Follett, P., Jensen, F. E., Ratan, R., Rosenberg, P. A., Volpe, J. J., & Vartanian, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432609100 · Cited by 1,052
Microglial Activation and Chronic Neurodegeneration
Lull, M. E., & Block, M. L. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.014 · Cited by 1,047
Non–cell autonomous toxicity in neurodegenerative disorders: ALS and beyond
Ilieva, H., Polymenidou, M., & Cleveland, D. W. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200908164 · Cited by 1,008
“Although these efforts did not produce disease (Pramatarova et al., 2001; Lino et al., 2002), a later study succeeded with mutant synthesis largely restricted to neurons, using mutant SOD1 expression driven by neuron-specific Thy1.”
Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat
McCormack, A. L., Thiruchelvam, M. J., Manning-Bog, A., Thiffault, C., Langston, J. W., Cory‐Slechta, D. A., & Monte, D. A. D. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0507 · Cited by 838
Genetic Animal Models of Parkinson's Disease
Dawson, T. M., Ko, H. S., & Dawson, V. L. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.034 · Cited by 866
Self-citation
Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression
Gao, H., & Hong, J. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.05.002 · Cited by 852
Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson’s Disease
Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789
S -Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function
Chung, K. K. K., Thomas, B., Li, X., Pletniková, O., Troncoso, J. C., Marsh, L., Dawson, V. L., & Dawson, T. M. (2004) · Science · doi:10.1126/science.1093891 · Cited by 772
Self-citation
Oxidatively modified proteins in aging and disease1, 2 1Guest Editor: Earl Stadtman 2This article is part of a series of reviews on “Oxidatively Modified Proteins in Aging and Disease” The full list of papers may be found on the homepage of the journal
Beal, M. F. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00780-3 · Cited by 763
Dementia with Lewy bodies.
McKeith, I. G. (2004) · Europe PMC (PubMed Central) · Cited by 756
Oxidative stress and nitration in neurodegeneration: Cause, effect, or association?
Ischiropoulos, H., & Beckman, J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317638 · Cited by 759
Parkinson's disease
Thomas, B., & Beal, M. F. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm159 · Cited by 748
Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response
Bachiller, S., Jiménez-Ferrer, I., Paulus, A., Yang, Y., Swanberg, M., Deierborg, T., & Boza‐Serrano, A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00488 · Cited by 750
Inflammatory Neurodegeneration Mediated by Nitric Oxide from Activated Glia-Inhibiting Neuronal Respiration, Causing Glutamate Release and Excitotoxicity
Bal-Price, A., & Brown, G. C. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06480.2001 · Cited by 686
“…neurons in coculture (Chao, 1996; Hu et al., 1997; Kingham et al., 1999; Tanabe et al., 1999), and this may occur in vivo during brain trauma, inflammation, post-ischemia, and infection, and in neurodegenerative diseases (Loihl and Murphy, 1998; Bolanos and Almeida, 1999; Liberatore et al., 1999).”
Background
Heterogeneity of CNS myeloid cells and their roles in neurodegeneration
Prinz, M., Priller, J., Sisodia, S. S., & Ransohoff, R. M. (2011) · Nature Neuroscience · doi:10.1038/nn.2923 · Cited by 674
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration
Teismann, P., Tieu, K., Choi, D., Wu, D., Naini, A., Hunot, S., Vila, M., Jackson-Lewis, V. R., & Przedborski, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0837397100 · Cited by 671
Self-citation
Experimental models of Parkinson's disease
Beal, M. F. (2001) · Nature reviews. Neuroscience · doi:10.1038/35072550 · Cited by 645
NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease
Wu, D., Teismann, P., Tieu, K., Vila, M., Jackson-Lewis, V. R., Ischiropoulos, H., & Przedborski, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937239100 · Cited by 634
Self-citation
Inflammation as a causative factor in the aetiology of Parkinson's disease
Whitton, P. S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707167 · Cited by 641
“Furthermore, the deletion of inflammatory iNOS using gene targeting has been shown to have a neuroprotective effect in MPTP-treated mice (Liberatore et al., 1999; Dehmer et al., 2000).”
Background
Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention
Tansey, M. G., McCoy, M. K., & Frank-Cannon, T. C. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.004 · Cited by 587
“Loss of DA neurons in MPTP models is associated with a glial response that peaks prior to the death of neurons (Czlonkowska et al., 1996; Kohutnicka et al., 1998; Liberatore et al., 1999; Dehmer et al., 2000; Vila et al., 2001).”
Background
Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP
Dauer, W. T., Kholodilov, N. G., Vila, M., Trillat, A., Goodchild, R. E., Larsen, K. E., Staal, R. G. W., Tieu, K., Schmitz, Y., Yuan, C. A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172514599 · Cited by 595
Self-citation
Nitric oxide, cell bioenergetics and neurodegeneration
Moncada, S., & Bolaños, J. P. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03988.x · Cited by 555
Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease
Beal, M. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07470.x · Cited by 529
Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment
Davidson, C., Gow, A. J., Lee, T. H., & Ellinwood, E. H. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00054-6 · Cited by 518
MPTP Mouse Models of Parkinson’s Disease: An Update
Meredith, G. E., & Rademacher, D. J. (2011) · Journal of Parkinson's Disease · doi:10.3233/jpd-2011-11023 · Cited by 471
“The expression of iNOS in activated microglia contributes to the death of DAergic neurons in MPTP toxicity [67, 68].”
Background
Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
Hald, A., & Lotharius, J. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.01.013 · Cited by 510
Neurotoxin-based models of Parkinson's disease
Bové, J., & Perier, C. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.10.057 · Cited by 534
“In the acute mouse model, astrocytosis parallels dopaminergic-cell death (Liberatore et al., 1999; Członkowska et al., 1996; Kohutnicka et al., 1998), suggesting that astrocytic reaction is secondary to the neuronal death.”
Background
Estrogen Prevents the Lipopolysaccharide-Induced Inflammatory Response in Microglia
Vegeto, E., Bonincontro, C., Pollio, G., Sala, A., Viappiani, S., Nardi, F., Brusadelli, A., Viviani, B., Ciana, P., & Maggi, A. C. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-06-01809.2001 · Cited by 475
“These observations are substantiated by the results in human neurodegenerative diseases and in the correspondent experimental animal models (Bo et al., 1994; Bagasra et al., 1995; Van Dam et al., 1995; Adamson et al., 1996; Liberatore et al., 1999).”
Result
Inflammatory Neurodegeneration Mediated by Nitric Oxide, Glutamate, and Mitochondria
Brown, G. C., & Bal‐Price, A. (2003) · Molecular Neurobiology · doi:10.1385/mn:27:3:325 · Cited by 467
Translocator protein 18 kDa (TSPO): Molecular sensor of brain injury and repair
Chen, M.-K., & Guilarte, T. R. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.12.004 · Cited by 506
“On the other hand, astrocytes become activated sometime after microglia but they appear to have a more protracted period of activation than microglia (Chen et al., 2004; Guilarte 2004; Kuhlmann and Guilarte, 2000; Liberatore et al., 1999; McCann et al., 1996).”
Background
Oxidative Stress in Parkinson's Disease
Zhou, C. H., Huang, Y., & Przedborski, S. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.023 · Cited by 460
Self-citation
The Role of Glial Reaction and Inflammation in Parkinson's Disease
Hirsch, É. C., Breidert, T., Rousselet, E., Hunot, S., Hartmann, A., & Michel, P. P. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07478.x · Cited by 455
Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease
Lobsiger, C. S., & Cleveland, D. W. (2007) · Nature Neuroscience · doi:10.1038/nn1988 · Cited by 448
Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult
Paxinou, E., Chen, Q., Weisse, M., Giasson, B. I., Norris, E. H., Rueter, S. M., Trojanowski, J. Q., Lee, V. M. ‐., & Ischiropoulos, H. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-20-08053.2001 · Cited by 440
“…in human neurodegenerative diseases as well as animal models of neurodegeneration has been provided (Smith et al., 1997; Ara et al., 1998; Good et al., 1998; Hensley et al., 1998; Liberatore et al., 1999; Duda et al., 2000b; Received June 7, 2001; revised July 31, 2001; accepted Aug. 8, 2001.”
Background
Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminergic Neurodegeneration
Gao, H., Kotzbauer, P. T., Uryu, K., Leight, S., Trojanowski, J. Q., & Lee, V. M. ‐. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0143-07.2008 · Cited by 453
“, 1999), and animal models of PD created by MPTP, 6-OHDA, or rotenone (Liberatore et al., 1999; Cicchetti et al., 2002; Sherer et al., 2003).”
Background
Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease
Gelders, G., Baekelandt, V., & Van der Perren, A. (2018) · Journal of Immunology Research · doi:10.1155/2018/4784268 · Cited by 430
“This model also provided evidence for the direct involvement of activated microglia in the processes leading to neuronal cell death as microglial activation precedes neuronal degeneration [35, 61, 63].”
Background
JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease
Hunot, S., Vila, M., Teismann, P., Davis, R. J., Hirsch, É. C., Przedborski, S., RAKIC, P. T., & Flavell, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307453101 · Cited by 430
Self-citation
Glia: Initiators and progressors of pathology in Parkinson's disease
Halliday, G. M., & Stevens, C. H. (2011) · Movement Disorders · doi:10.1002/mds.23455 · Cited by 436
“6-hydroxydopamine animal models and in MPTP mice lacking the iNOS gene.(88) Increased concentrations of the proinflammatory cytokines have been identified in the striatum, SN,(112) serum, and cerebrospinal fluid in patients with PD.”
Background
D-β-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease
Tieu, K., Perier, C., Caspersen, C., Teismann, P., Wu, D.-C., Yan, S.-D., Naini, A., Vila, M., Jackson-Lewis, V., Ramasamy, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318797 · Cited by 497
Self-citation
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease
Reynolds, A. D., Banerjee, R., Liu, J., Gendelman, H. E., & Mosley, R. L. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0507296 · Cited by 423
“Of the microglial secretory factors known to influence secondary degeneration, TNF- and iNOS are implicated in stimulating the dopaminergic cell loss observed following MPTP intoxication [21].”
Background
Regulatory T Cells Attenuate Th17 Cell-Mediated Nigrostriatal Dopaminergic Neurodegeneration in a Model of Parkinson’s Disease
Reynolds, A. D., Stone, D. K., Hutter-Saunders, J. A. L., Benner, E. J., Mosley, R. L., & Gendelman, H. E. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901852 · Cited by 417
“Total numbers of Mac-1 cells, CD4 T cells, and TH- and Nissl-stained neurons in the SN were estimated by stereological analysis with Stereo Investigator software (MBF Bioscience, Williston, VT), using the optical fractionator module (22).”
Method
Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease
Zhang, Y., Dawson, V. L., & Dawson, T. M. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0319 · Cited by 408
Self-citation
The molecular bases of Alzheimer’s disease and other neurodegenerative disorders
Maccioni, R. B., Muñoz, J. P., & Barbeito, L. (2001) · Archives of Medical Research · doi:10.1016/s0188-4409(01)00316-2 · Cited by 474
Neuroinflammatory processes in Parkinson's disease
Hunot, S., & Hirsch, É. C. (2003) · Annals of Neurology · doi:10.1002/ana.10481 · Cited by 407
Nitric oxide and neuronal death
Brown, G. C. (2010) · Nitric Oxide · doi:10.1016/j.niox.2010.06.001 · Cited by 396
Plasma Urate and Risk of Parkinson's Disease
Weisskopf, M. G., O’Reilly, É. J., Chen, H., Schwarzschild, M. A., & Ascherio, A. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm127 · Cited by 395
Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease
Mosley, R. L., Benner, E. J., Kadiu, I., Thomas, M., Boska, M. D., Hasan, K. M., Laurie, C. D., & Gendelman, H. E. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.006 · Cited by 393
“Ablation by genetic manipulation or inhibition with specific pharmaceutical agents protects nigral neurodegeneration induced by MPTP [96,228,229], LPS [222] or 6-OHDA [197], but is less active at protecting striatal termini [96,228].”
BackgroundInfluential
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation
Dehmer, T., Heneka, M. T., Sastre, M., DICHGANS, J., & Schulz, J. B. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02210.x · Cited by 387
“Similar results were obtained by us and others in iNOS-deficient mice (Liberatore et al. 1999; Dehmer et al. 2000).”
BackgroundResultInfluential
The MPTP model of Parkinson's disease
Smeyne, R. J., & Jackson-Lewis, V. R. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.09.017 · Cited by 387
Self-citation
Neuroinflammation and α-Synuclein Dysfunction Potentiate Each Other, Driving Chronic Progression of Neurodegeneration in a Mouse Model of Parkinson’s Disease
Gao, H.-M., Zhang, F., Zhou, H., Kam, W., Wilson, B., & Hong, J.-S. (2011) · Environmental Health Perspectives · doi:10.1289/ehp.1003013 · Cited by 355
“Morphologic changes of microglia (the resident brain immune cells) and accumulation of pro inflammatory factors are associated with degenerating DA neurons in the substantia nigra (SN) of PD patients and various PD animal models (Liberatore et al. 1999; McGeer et al. 1988; Sherer et al. 2003).”
Background
Protective action of the peroxisome proliferator‐activated receptor‐γ agonist pioglitazone in a mouse model of Parkinson's disease
Breidert, T., Callebert, J., Heneka, M. T., Landreth, G. E., Launay, J., & Hirsch, É. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00990.x · Cited by 381
Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease
Vila, M., Jackson-Lewis, V. R., Vukosavić, S., Djaldetti, R., Liberatore, G. T., Offen, D., Korsmeyer, S. J., & Przedborski, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633998 · Cited by 373
Self-citation
HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration
Gao, H.-M., Zhou, H., Zhang, F., Wilson, B. C., Kam, W., & Hong, J.-S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3732-10.2011 · Cited by 369
“The expression of Mac1 is elevated in PD brains (Liberatore et al., 1999).”
Background
Reactive Astrocytes As Therapeutic Targets for CNS Disorders
Hamby, M. E., & Sofroniew, M. V. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.07.003 · Cited by 381
Cellular pathology of Parkinson?s disease: astrocytes, microglia and inflammation
Teismann, P., & Schulz, J. B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0944-0 · Cited by 371
“…astrocytic activation parallels the time course of dopaminergic cell death in the SNpc as well as striatum and GFAP-expression remains upregulated even after most of dopaminergic neurons have died due to MPTP intoxication (Czlonkowska et al. 1996; Kohutnicka et al. 1998; Liberatore et al. 1999).”
BackgroundInfluential
Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons
Benner, E. J., Banerjee, R., Reynolds, A. D., Sherman, S., Писарев, В. М., Tsiperson, V., Nemachek, C., Ciborowski, P. S., Przedborski, S., Mosley, R. L., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001376 · Cited by 371
“nal loss in animal models of PD [66,67].”
BackgroundSelf-citation
The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?
Monte, D. A. D. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00501-5 · Cited by 358
Aberrant Protein S-Nitrosylation in Neurodegenerative Diseases
Nakamura, T., Tu, S., Akhtar, M. W., Sunico, C. R., Okamoto, S., & Lipton, S. A. (2013) · Neuron · doi:10.1016/j.neuron.2013.05.005 · Cited by 361
Regulation of Inducible Nitric Oxide Synthase Gene in Glial Cells
Saha, R. N., & Pahan, K. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.929 · Cited by 354
“Similarly, administration of MPTP in C57/BL6 mice leads to robust gliosis marked by upregulation of glial iNOS (83).”
Mechanism-Based Molecular Design of Highly Selective Fluorescence Probes for Nitrative Stress
Ueno, T., Urano, Y., Kojima, H., & Nagano, T. (2006) · Journal of the American Chemical Society · doi:10.1021/ja061972v · Cited by 351
MAPK signaling in neurodegeneration: influences of flavonoids and of nitric oxide
Schroeter, H., BOYD, C., SPENCER, J., WILLIAMS, R., Cadenas, E., & Rice-Evans, C. A. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00075-1 · Cited by 338
“Furthermore, microglia activation during neuroinflammation is associated with induction of inducible nitric oxide synthase (iNOS) expression leading to a large and sustained NO • production, which also appears to be causally linked to neuronal apoptosis and neurodegeneration [100,121].”
Background
Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review)
Guo, J., Zhao, X., Li, Y., Li, G., & Liu, X. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3406 · Cited by 353
“Microglia activation promotes the production of proinflammatory cytokines, which cause dopaminergic nigrostriatal neuron degeneration in MPTP models of PD (123).”
Background
Pathogenesis of Parkinson's disease
Hirsch, E. C., Jenner, P., & Przedborski, S. (2013) · Movement Disorders · doi:10.1002/mds.25032 · Cited by 336
Self-citation
Activation of microglia by human neuromelanin is NF‐κB‐dependent and involves p38 mitogen‐activated protein kinase: implications for Parkinson's disease
Wilms, H., Rosenstiel, P. C., Sievers, J., Deuschl, G., Zecca, L., & Lucius, R. (2003) · The FASEB Journal · doi:10.1096/fj.02-0314fje · Cited by 337
“Because levels of TNF-α are increased in postmortem brain and CSF from patients with PD, and TNF-α mediates cell death in a sensitive population of dopaminergic neurons in vitro (41), such results support the hypothesis of an involvement of proinflammatory cytokines in the degeneration of dopaminergic neurons in PD.”
BackgroundResult
Deficiency of Inducible Nitric Oxide Synthase Protects Against MPTP Toxicity In Vivo
Dehmer, T., Lindenau, J. H., Haid, S., DICHGANS, J., & Schulz, J. B. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742213.x · Cited by 337
Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation
Bureau, G., Longpré, F., & Martinoli, M. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21503 · Cited by 344
“Activation of microglia leads to an increase in the production of cytokines that could mediate neuronal apoptosis and precedes degeneration of DA nigrostriatal neurons in a PD mouse model (Liberatore et al., 1999).”
Background
Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment
Petroske, E., Meredith, G. E., Callen, S. E., Totterdell, S., & Lau, Y.-S. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00295-0 · Cited by 334
“, 1998), but some have used unbiased stereology to estimate their numbers (Chadi et al., 1993; Liberatore et al., 1999; Walters et al., 1999).”
BackgroundMethod
Reactive Nitrogen Species: Molecular Mechanisms and Potential Significance in Health and Disease
Martínez, M. C., & Andriantsitohaina, R. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1993 · Cited by 345
“RNS-dependent mechanisms contribute to neurodegeneration in Parkinson’s disease, as shown by the increased expression of iNOS in Parkinson experimental models associated with dopaminergic neuronal loss (178, 237).”
Novel anti-inflammatory therapy for Parkinson's disease
Gao, H., Liu, B., Zhang, W., & Hong, J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00176-7 · Cited by 325
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease
Benner, E. J., Mosley, R. L., Destache, C. J., Lewis, T. B., Jackson-Lewis, V. R., Gorantla, S., Nemachek, C., Green, S. R., Przedborski, S., & Gendelman, H. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400569101 · Cited by 321
Self-citation
Selective microglial activation in the rat rotenone model of Parkinson's disease
Sherer, T., Betarbet, R. S., Kim, J.-H., & Greenamyre, J. T. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00172-1 · Cited by 317
PPARs in the brain
HENEKA, M., & LANDRETH, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.016 · Cited by 317
Chronic stress and glucocorticoids: From neuronal plasticity to neurodegeneration
Vyas, S., Rodrigues, A. J., Silva, J. M., Tronche, F., Almeida, O. F. X., Sousa, N., & Sotiropoulos, I. (2016) · Neural Plasticity · doi:10.1155/2016/6391686 · Cited by 297
Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease
Drechsel, D. A., & Patel, M. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.02.008 · Cited by 314
Involvement of Interferon-γ in Microglial-Mediated Loss of Dopaminergic Neurons
Mount, M. P., Lira, A., Grimes, D., Smith, P. D., Faucher, S., Slack, R. S., Anisman, H., Hayley, S. P., & Park, D. S. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.5321-06.2007 · Cited by 331
“This notion is supported by the fact that MPTP (MPP metabolite) can directly target mitochondria in neurons and lead to increased ROS and damage (Liberatore et al., 1999; Dehmer et al., 2000; Gonzalez-Polo et al., 2004; Chen et al., 2006).”
Background
Glutathione—a review on its role and significance in Parkinson's disease
Martin, H. L., & Teismann, P. (2009) · The FASEB Journal · doi:10.1096/fj.08-125443 · Cited by 320
An inflammatory review of Parkinson's disease
Orr, C. F., Rowe, D. B., & Halliday, G. M. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00127-2 · Cited by 309
Microglial phenotypes in Parkinson’s disease and animal models of the disease
Joers, V., Tansey, M. G., Mulas, G., & Carta, A. R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.006 · Cited by 285
“An increase of mRNA and protein for inflammatory cytokines, such as IL-1β, TNF and IL-6, has been consistently reported after acute MPTP exposure together with an increase of inducible nitric oxide synthase (iNOS) levels, suggesting that reactive microglia acquired an early pro-inflammatory phenotype in this model (Bi…”
Background
Injections of an opioid antagonist into the locus coeruleus and periaqueductal gray but not the amygdala precipitates morphine withdrawal in the 7‐day‐old rat
Jones, K. L., & Barr, G. A. (2000) · Synapse · doi:10.1002/1098-2396(200102)39:2 · Cited by 11
Critical role of microglial NADPH oxidase‐derived free radicals in the in vitro MPTP model of Parkinson's disease
Gao, H., Liu, B., Zhang, W., & Hong, J. (2003) · The FASEB Journal · doi:10.1096/fj.03-0109fje · Cited by 306
“Recent reports indicate that glia participate in MPTP-induced dopaminergic neurodegeneration in the rodent PD model (10, 11, 14, 15, 26).”
BackgroundInfluential
Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease
Taylor, J. M., Main, B. S., & Crack, P. J. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.016 · Cited by 313
“Increased levels of iNOS have also been reported in mice injected with MPTP, while mice lacking the gene for iNOS display protection against MPTP-induced DA degeneration (Liberatore et al., 1999).”
Background
Neuroglia in neurodegeneration
Heneka, M. T., Rodriguez, J. J., & Verkhratsky, A. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.11.004 · Cited by 316
Oxidative and nitrosative stress in Parkinson's disease
Tsang, A. H. K., & Chung, K. K. K. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.12.006 · Cited by 300
“This pathogenic mechanism has been verified in iNOS and nNOS knock out mice in which these animals are resistant to MPTP induced toxicity [106, 107].”
Background
Astrogliosis in CNS Pathologies: Is There A Role for Microglia?
Zhang, D., Hu, X., Li, Q., O'Callaghan, J. P., & Hong, J. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8098-4 · Cited by 305
“In MPTP-induced neuropathological damage in mice, activation of microglia peaked at 2 days and activation of astrocyte peaked at 4 days after injection [83].”
Neuroinflammatory processes in Parkinson's disease
Hirsch, É. C., Hunot, S., & Hartmann, A. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.10.013 · Cited by 303
“[39] Liberatore GT, JacksonLewis V, Vukosavic S, Mandir AS, Vila M,”
BackgroundResultInfluential
The influence of microglia on the pathogenesis of Parkinson's disease
Long-Smith, C. M., Sullivan, A. M., & Nolan, Y. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.08.001 · Cited by 302
Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps
Levy, O. A., Malagelada, C., & Greene, L. A. (2009) · APOPTOSIS · doi:10.1007/s10495-008-0309-3 · Cited by 300
“NADPH oxidase or iNOS null mice have less nigral cell loss and less oxidative damage in response to MPTP [153, 182].”
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease.
Przedborski, S., & Vila, M. (2003) · PubMed · Cited by 286
Self-citation
Ablation of the Inflammatory Enzyme Myeloperoxidase Mitigates Features of Parkinson's Disease in Mice
Choi, D., Pennathur, S., Perier, C., Tieu, K., Teismann, P., Wu, D.-C., Jackson-Lewis, V. R., Vila, M., Vonsattel, J., Heinecke, J. W., et al. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0970-05.2005 · Cited by 286
“However, epidemiological studies suggest that inflammation increases the risk of developing PD (Chen et al., 2003), and experimental models of PD show that inflammatory oxidants modulate SNpc dopaminergic neuronal death (Liberatore et al., 1999; Gao et al., 2002; Wu et al., 2002, 2003).”
BackgroundInfluentialSelf-citation

Authors: Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S.
Affiliations: Columbia University (US)
Johns Hopkins University (US)
Rutgers, The State University of New Jersey (US)
Corresponding author: Przedborski, Serge
ORCID: Vila, Miquel
Dawson, Valina L.
Dawson, Ted M.
Przedborski, Serge
Venue: Nature Medicine
Publisher: Springer Science and Business Media LLC
Published: 1999-12
Volume: 5
Issue: 12
Pages: 1403-1409
ISSN: 1078-8956 (ISSN-L)
1546-170X
DOI: 10.1038/70978
OpenAlex: W1530199299
Cited by: 1,046
References: 53
Citations by year: 2026: 9 · 2025: 11 · 2024: 10 · 2023: 19 · 2022: 20 · 2021: 27 · 2020: 22 · 2019: 31 · 2018: 43 · 2017: 35 · 2016: 44 · 2015: 41 · 2014: 45 · 2013: 49 · 2012: 52
FWCI: 25.39
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (unspecified)
Locations: Nature Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r29ns037345-05)
National Institute of Neurological Disorders and Stroke (P50-NS38370, R01 NS 38586, R29 NS37345, R01NS038586, P50NS038370)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: inducible nitric oxide synthase, MPTP, Parkinson's disease, dopaminergic neuron loss, substantia nigra pars compacta, gliosis, iNOS knockout mice, neuroprotection, iNOS inhibitors, neurotoxicity
MeSH terms: Animals, Disease Models, Animal, Dopamine, Enzyme Inhibitors, Male, Mice, Inbred C57BL, Nerve Degeneration, Parkinson Disease, RNA, Messenger, Gene Expression, Microglia, Mice, Knockout, Nitric Oxide Synthase, MPTP Poisoning, Mice, Nitric Oxide Synthase Type II

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks